TrialSignal transduction and targeted therapy2024

First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 study.

Ning Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.